The Myeloproliferative Neoplasms Channel on VJHemOnc is an independent medical education platform, supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2022 | Ruxolitinib, pacritinib, fedratinib or momelotinib for thrombocytopenic patients with myelofibrosis
Claire Harrison, MD, DM, FRCP, FRCPath, Guy’s and St Thomas’ NHS Foundation Trust, London, UK, comments on the use of different JAK inhibitors including ruxolitinib, pacritinib, fedratinib, or momelotinib for treatment of patients with myelofibrosis (MF) who are thrombocytopenic, highlighting the results of recent retrospective analyses comparing pacritinib with ruxolitinib, and fedratinib with ruxolitinib in this setting. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.
Disclosures
Research funding: Celgene, Constellation, Novartis Advisory role: AbbVie, AOP, BMS, Celgene, CTI, Novartis, Galacteo, Geron, Gilead, Janssen, Keros, Promedior, Roche, Shire, Sierra
